In line with this, cenicriviroc, an oral dual CCR2/CCR5 antagonist, has demonstrated anti-fibrotic effects in a thioacetamide-induced rat liver fibrosis model and in a mouse model of diet-induced NASH (40). Here, CCR2 is linked to Hepatic fibrosis.